Recurrence, mortality rates better in nevus-associated vs. de novo acral melanoma
Source: Healio, January 2025
Key takeaways:
- Five-year recurrence-free survival was 55.1% with nevus-associated acral melanoma (NAAM) vs. 42.3% with de novo acral melanoma (DNAM).
- Overall 5-year survival was 75.1% vs. 63.2% in the NAAM vs. DNAM groups.
Recurrence-free survival and overall survival were more common in patients with nevus-associated acral melanoma compared with those with de novo acral melanoma, according to a study.
“Nevus-associated melanoma (NAM) refers to melanoma that either contains residual nevus components, as observed in histopathological examination, or originates from a pre-existing melanoma,” Yiqun Zhang, MM, of the department of oncology at the First Hospital of Jilin University, and colleagues wrote. “Patients with NAM show better overall survival (OS) compared to those with de novo melanoma (DNM).”